In addition, the FDA has granted tentative approval to Amneal’s rifaximin 550 mg oral tablets, whic BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application ...
Hosted on MSN10mon
New Jersey drug company to provide cash, naloxone to Delaware in latest opioid settlementNew Jersey-based drug manufacturer Amneal Pharmaceuticals has become the latest company to reach a settlement agreement with Delaware and other states for its role in fueling the opioid crisis ...
Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience ...
Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus. 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback